Brain Tumor Radiogenomic Classification of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning

被引:6
|
作者
Sakly, Houneida [1 ]
Said, Mourad [2 ]
Seekins, Jayne [3 ]
Guetari, Ramzi [4 ]
Kraiem, Naoufel [1 ,5 ]
Marzougui, Mehrez [6 ]
机构
[1] Manouba Univ, RIADI Lab, ENSI, Campus Univ La Manouba, La Manouba 2010, Tunisia
[2] Int Ctr Carthage Med Monastir, Radiol & Med Imaging Unit, Monastir, Tunisia
[3] Stanford Univ, Dept Radiol, Sch Med, Stanford, CA USA
[4] Univ Carthage, Polytech Sch Tunisia, SERCOM Lab, La Marsa, Tunisia
[5] King Khalid Univ, Coll Comp Sci, Abha, Saudi Arabia
[6] Univ Monastir, Elect & Microelect Lab, Monastir, Tunisia
关键词
artificial intelligence; big data; brain tumor; radiogenomic; classification; O6-methylguanine-DNA methyltransferase promoter methylation; Transfer learning; HIGH-GRADE GLIOMAS; NEURAL-NETWORKS; MGMT; MRI; RADIOMICS; GLIOBLASTOMA; PREDICTION; SURVIVAL; PERFUSION; IMAGES;
D O I
10.1177/10732748231169149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Artificial Intelligence (AI) is the subject of a challenge and attention in the field of oncology and raises many promises for preventive diagnosis, but also fears, some of which are based on highly speculative visions for the classification and detection of tumors. A brain tumor that is malignant is a life-threatening disorder. Glioblastoma is the most prevalent kind of adult brain cancer and the 1 with the poorest prognosis, with a median survival time of less than a year. The presence of O-6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation, a particular genetic sequence seen in tumors, has been proven to be a positive prognostic indicator and a significant predictor of recurrence.This strong revival of interest in AI is modeled in particular to major technological advances which have significantly increased the performance of the predicted model for medical decision support. Establishing reliable forecasts remains a significant challenge for electronic health records (EHRs). By enhancing clinical practice, precision medicine promises to improve healthcare delivery. The goal is to produce improved prognosis, diagnosis, and therapy through evidence-based sub stratification of patients, transforming established clinical pathways to optimize care for each patient's individual requirements. The abundance of today's healthcare data, dubbed "big data," provides great resources for new knowledge discovery, potentially advancing precision treatment. The latter necessitates multidisciplinary initiatives that will use the knowledge, skills, and medical data of newly established organizations with diverse backgrounds and expertise.The aim of this paper is to use magnetic resonance imaging (MRI) images to train and evaluate your model to detect the presence of MGMT promoter methylation in this competition to predict the genetic subtype of glioblastoma based transfer learning. Our objective is to emphasize the basic problems in the developing disciplines of radiomics and radiogenomics, as well as to illustrate the computational challenges from the perspective of big data analytics.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Promoter hypermethylation of O6-methylguanine-DNA methyltransferase gene in gliomas
    Ohgaki, H
    Nakamura, M
    Watanabe, T
    Kleihues, P
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (05): : 534 - 534
  • [2] Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation
    Storey, Katie
    Leder, Kevin
    Hawkins-Daarud, Andrea
    Swanson, Kristin
    Ahmed, Atique U.
    Rockne, Russell C.
    Foo, Jasmine
    JCO CLINICAL CANCER INFORMATICS, 2019, 3 : 1 - 12
  • [3] O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas
    Koos, B.
    Peetz-Dienhart, S.
    Riesmeier, B.
    Fruehwald, M. C.
    Hasselblatt, M.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2010, 36 (04) : 356 - 358
  • [4] Individualized chemotherapy for malignant astrocytomas based on O6-methylguanine-DNA methyltransferase methylation analysis
    Watanabe, T
    Ogino, A
    Ohta, T
    Yoshino, A
    Katayama, Y
    NEURO-ONCOLOGY, 2005, 7 (03) : 311 - 311
  • [5] PROGNOSTIC IMPACT OF O6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION IN MEDULLOBLASTOMA
    Kondo, Akihide
    Kurimoto, Tomoko
    Sakaguchi, Sachi
    Arai, Hajime
    NEURO-ONCOLOGY, 2015, 17 : 21 - 21
  • [6] O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma
    Yeager, ND
    Dolan, ME
    Gastier, JM
    Gross, TG
    Delaney, S
    Frick, J
    Ruymann, FB
    Ewesuedo, R
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (12) : 941 - 947
  • [7] Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
    Lam, Keng
    Eldred, Blaine S. C.
    Kevan, Bryan
    Pianka, Sean
    Eldred, Brittany A.
    Rinonos, Serendipity Zapanta
    Yong, William H.
    Liau, Linda M.
    Nghiemphu, Phioanh L.
    Cloughesy, Timothy F.
    Green, Richard M.
    Lai, Albert
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [8] The promoter methylation status of the DNA repair gene O6-methylguanine-DNA methyltransferase in ulcerative colitis
    Shunji Matsumura
    Naohide Oue
    Reiko Ito
    Hirofumi Nakayama
    Yasuhiko Kitadai
    Hiroshi Yokozaki
    Kazuaki Chayama
    Wataru Yasui
    Virchows Archiv, 2003, 443 : 518 - 523
  • [9] The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma
    Bujko, Mateusz
    Kowalewska, Magdalena
    Danska-Bidzinska, Anna
    Bakula-Zalewska, Elwira
    Siedecki, Janusz A.
    Bidzinski, Mariusz
    ONCOLOGY LETTERS, 2012, 4 (03) : 551 - 555
  • [10] Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage
    Sansone, Giulio
    Lombardi, Giuseppe
    Maccari, Marta
    Gaiola, Matteo
    Pini, Lorenzo
    Cerretti, Giulia
    Guerriero, Angela
    Volpin, Francesco
    Denaro, Luca
    Corbetta, Maurizio
    Salvalaggio, Alessandro
    BRAIN COMMUNICATIONS, 2024, 6 (06)